3sbio, Inc. · HKEX:1530
3sbio — FY2024 Earnings Presentation
48 slides from 3sbio's earnings presentation, Mar 26, 2025
Slide 1: 2024 Annual Results Presentation
2024 Annual Results Presentation 26 March, 2025
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Agenda
Agenda Highlights Business R&D Financial Q&A Overview Review 1 2 3 4 5 3
Slide 4: 01 Highlights
01 Highlights
Slide 5: 2024 Annual Results Abstract
2024 Annual Results Abstract Net Profit Attributable to Net profit attributable Owners of the Parent Financial Revenue Gross profit to parent Adjusted for Non-Operating Resource Items 16.5% 17.9% 34.9% 18.8% 8.1Bn YOY YOY YOY YOY GPM：86.0 % Bn RMB Bn RMB Bn RMB Bn RMB Bn RMB 9.1 8.2 8.1 2.3 7.4 7.8
Slide 6: 2024 Business Milestones
2024年业务里程碑 • 《Clinical Guidelines • • Studies of • Cooperation with Haihe • TPIAO ® • 《Primary liver cancer TPIAO ® Phase III • TPIAO ® NDA • 707 Partial PhII Hematology/ • Studies of TPIAO® were for Renal Study of CLDT of CLDT was Inetetamab were Biopharma in respect of data was presented at APASL,
Slide 7: 02 Business Overview
02 Business Overview
Slide 8: TPIAO- Global Exclusive Commercialized rhTPO
TPIAO- Global Exclusive Commercialized rhTPO Revenue of TPIAO, 2024 Top 1 market share 1 67% 1 market share in terms of sales, still tops the first position in rhTPO products RMB Mn YOY：20.4% 66.6% 5,062 4,205 3,397 3,080 2,762 TPIAO Class A（Interleukin-11） 2020 2021 2022 2023 2024 Class B（Oral TPO-
Slide 9: TPIAO: Maintain competitive edge in diversified Market
TPIAO：Maintain competitive edge in diversified Market TPIAO,TPO-RA and Romiplostim: Competitive Advantage Jointly take replacement of IL-11 Market share of Thrombopoietic agents -sales volume ✓ The only specific ascending plate drug with 2024 CIT indication; 34.3% 73.6% TPIAO 70.2% TPO-RA 31.4% ✓ Gu
Slide 10: TPIAO- Improving Cancer Patients Coverage
TPIAO- Improving Cancer Patients Coverage Chemotherapy Cancer therapy induced Chronic liver Primary immune Got SIT，HRT Expert Myelogenous induced thrombocytopenia（CTIT）got Pediatric disease related acute thrombocytopenia thrombocytopenia Grade A recommendation in Consensus preferred thrombocytopenia
Slide 11: rhEPO- EPIAO & SEPO
rhEPO- EPIAO & SEPO Revenue of rhEPO, 2024 TOP 1 Market share 1 Two brands dominate 42%1 market share, preside Top 1 position in terms of EPO market share RMB Mn YOY：8.3% • EPIAO® quality standard is consistent with EU Pharmacopeia • CKD anemia, CIA and Perioperative anemia in included in NRDL 1,120
Slide 12: Mandi – Effective & Reliable Hair Growth Drug
Mandi – Effective & Reliable Hair Growth Drug Revenue of Mandi, 2024 2nd Generation Mandi Foam • Approved with OTC in Jan 2024; RMB Mn • Innovative technology, fill the gap for skin sensitive population YOY：18.9% 1,337 1,124 894 602 368 2020 2021 2022 2023 2024 12
Slide 13: a) o o ro)
a) 0 o o ro)
Slide 14: R&D Pipeline-30 Candidates
R&D Pipeline-30 Candidates Therapeutic Area Candidates Pre-clinical IND Ph I Ph II Ph III NDA Nephrology SSS06 Long-acting rhEPO Remitch CLD pruritus NDA 2 SSS17 HIF inhibitor Pre-clinical TPO-106 CLDT NDA SSS20 Eltrombopag 304R anti-CD20 Ab ANDA 9 Hematology CS1003 anti-PD1 Ab IND& Phase I 602 anti
Slide 15: Innovation into Achievements
Innovation into Achievements 1 product Included in NRDL 4 NDAS accepted by CDE • Remitch: Included into NRDL 2024 1 ➢ SSS06 NuPIAO NDA of CKD anemia was accepted by CDE 2 products renewed in NRDL 2 ➢ 608 anti-IL-17A mAb • TPIAO、Cipterbin：Renewed in NRDL NDA of Adult PsO was accepted by CDE 2024 ➢ TP
Slide 16: Revenue about to Diversified
Revenue about to Diversified Mandi Potential Peak Sales： 10 Bn+ Semaglutide Winlevi ® Clascoterone minoxidil tincture Obesity Cream Dermatology / Metabolism EPO Remitch SSS06 SSS17 Recombinant Human Erythropoietin Nalfurafine Hydrochloride 2nd generation rESP HIF Inhibitor Orally Disintegrating Tabl
Slide 17: BD Cooperations-Expanding Commercial Territory
4 BD Cooperations-Expanding Commercial Territory Semaglutide Paclitaxel Oral Clifutinib DB-1303 (Obesity) Her-2 ADC Solution Besylate 2024 Apr 2024 Oct 2024 Nov 2024 Dec • Cooperation with Hybio Haihe Biopharma Sunshine Lake Duality Biologics • Obtain the exclusive rights of R&D, Pharma the exclusiv
Slide 18: Face Weight Management Broad Market- Semaglutide
Face Weight Management Broad Market- Semaglutide Chinese number of obese people Forecast of Chinese weight Overweight/obesity rate among loss drug market size1 (Est. 2030): adult Chinese residents >50% 329 mn 1 2020 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E Semaglutide: Globally re
Slide 19: BD cooperation-Paclitaxel Oral Solution
BD cooperation-Paclitaxel Oral Solution The exclusive oral formulation of paclitaxel in the world Leading the new model of LIPORAXEL® • Haihe Biopharma is responsible for the development and registration Cancer Home-based Treatment • NDA of GC1 has been approved in Sep 2024, BC 2 Ph III study has be
Slide 20: BD cooperation- Clifutinib
Professional Sales Team BD cooperation- Clifutinib Clififatinib Besylate Tablets: First-In-Class Highly Specific FLT3 Inhibitor Expected to be the first domestic FLT3-ITD mutation of relapsed/refractory AML targeted therapy drug AML cases in China China AML Drug Market Size Forecast1 • Acute myeloid
Slide 21: BD Cooperation- DB-1303 (Her2 ADC)
BD Cooperation- DB-1303 (Her2 ADC) No. of potential patients DB-1303 ✓ Synergy 3SBio commercialization capabilities in oncology space a 3rd generation HER2- ADC ✓ Strategic deployment of HER-2+ treatments > 300K HER2-Low Breast Cancer Only 1 ADC (Enhertu®）launched for HER2-low patients Leading High
Slide 22: Hematology & Oncology Pipeline
Hematology & Oncology Pipeline Candidates Indications IND Ph I Ph II Ph III CDE approved Monotherapy 1L PD-L1+NSCLC to start Phase III 707 1L NSCLC in Comb with Chemo anti-VEGF/PD-1 BsAb U.S. IND mCRC EC/PROC CLF2（common light chain Linear-Fabs- IgG）BsAb platform Partnership with Biokin Pharma：2025
Slide 23: 707: Preclinical Data Shows On Par or Improved Binding and Inhibition
707:Preclinical Data Shows On Par or Improved Binding and Inhibition 707 has Demonstrated Superior Activity at Lower Doses Compared to Another Late-Stage Drug (Drug A) VEGF Binding Affinity is Similar to Drug A… … with Improved PD-1 Binding Affinity … and Stronger Inhibition of HUVEC Proliferation c
Slide 24: 707: Summary of Ph I & Ph II Data From Ongoing Trials
707:Summary of Ph I &Ph II Data From Ongoing Trials 707 part of Ph II Data Analysis Phase (Trail) Phase 1a/1b Phase 2 Phase 2 Phase 2 1L PD-L1+ NSCLC ≥ 3L mCRC 1L mCRC 1L NSCLC Indication Advanced Solid Tumor without EGFR/ALK alterations, ECOG 0-1, RASm or BRAFm, RASm or BRAFm, without EGFR/ALK alte
Slide 25: 705: Treat on HER2 Expressing Tumors through Immunotherapy
705:Treat on HER2 Expressing Tumors through Immunotherapy anti-PD1/HER2 BsAb 705 • 705 connects ScFv of anti-PD1 to the heavy chain Fc segment of Trastuzumab through GGGGS, and simultaneously inhibits PD-1/PD-L1 signaling pathway and HER2 signaling pathway, which combines targeted therapy and immuno
Slide 26: 705-Phase I Clinical Data
705-Phase I Clinical Data 705 Phase I Trail Clinical Data（HER2+） Advanced Solid Tumor Prior Treatment HER2 PD-L1 Dosing Response ID Indication Lines Expression Expression Regimen Evaluation Breast Infiltrating Ductal 4L Failed S07005 IHC 3+ CPS 40 0.3mg/kg QW PD Carcinoma (HER2 Therapy Failed) 4L Fa
Slide 27: 706- Phase I Clinical Data
706- Phase I Clinical Data 706 Phase I Trail Clinical Data (Advanced Solid Tumor) 706 anti PD-1/PD-L1 BsAb Prior Treatment PD-L1 Dosing Response ID Indication Lines Expression Regimen Evaluation 2L Failed WEEK6:SD(-11%) S01001 GEJ CPS=1 0.01mg/kg QW （IO-R） WEEK12:SD(-9%) 1L Failed S04004 nsqNSCLC （D
Slide 28: Nephrology –More Pipelines & Indications
Nephrology –More Pipelines & Indications SSS06: High-glycosylated long-acting rESP Renal anemia with maintenance dialysis(CKD) EPO • CKD anemia CKD anemia: NDA accepted for review in 2024.7 • Cancer Related Anemia (CIA) NDA EPIAO • Perioperative Erythrocyte CIA: Phase II approved to proceed in 2024.
Slide 29: New Choice for Teenagers in Acne- Winlevi
New Choice for Teenagers in Acne- Winlevi® WS204 Clascoterone cream Acne vulgaris in 12 years and older 1st new mechanism of action in acne approved by the FDA in 40 years Bridging Trial Phase III All patients enrolled • Approved by FDA in Clinical trial shows: November 20211 Winlevi® could reduce t
Slide 30: Key Candidate-Autoimmune
Key Candidate-Autoimmune Build the Launched Pipeline&New Indication Pre-Clinical indications cover: Cover AD、CRSwNP、COPD、moderate build FIC/BIC most competitive RA、AS、PsO Autoimmune Pipeline in China to severe asthma, AG,etc. candidate Indication IND Ph I Ph II Ph III NDA NDA Moderate-to-severe PsO
Slide 31: Autoimmune: 608 (anti IL-17A mAb) in PsO
Autoimmune: 608 (anti IL-17A mAb) in PsO 608： Achieving a “Cure" aspiration for PsO Treatment Dosing interval extended to Q4W or Q8W in maintenance after 12 weeks ： W52: Efficacy of PASI75、sPGA0/1 and PASI90 responses was highly effective and sustained PASI75 PASI90 sPGA0/1 93.70 93.60 92.60 92.50 8
Slide 32: Autoimmune:613 anti-IL-1β mAb
Autoimmune:613 anti-IL-1β mAb 613: Comprehensive Disease Management for Gouty Arthritis Patients Enrollment of Phase III Acute Gouty Arthritis (PGF) Phase II One dose prevents Gouty Arthritis (AG) was results are positive and pre-III Progress ranks No.2 in China completed, with positive interim comm
Slide 33: Autoimmune:611 anti IL-4R mAb
Autoimmune:611 anti IL-4R mAb 611 Indications： • Adult AD: Phase III enrolment completed. Phase II trail shows better performance than control group. 200 million patients 11.6 billion USD • Adolescents AD: Phase II enrolment completed in China • AD in Children: Phase Ib/II enrolment completed 70 mil
Slide 34: Autoimmune: anti IL-5 mAb
Autoimmune: 610 anti IL-5 mAb 610：Ranks NO.1 Clin-progress in China • Phase III in Eosinophilic Asthma is enrolling, progress ranks No.1 in China. 19.92 Million 2.1 Bn USD Dosing Explore • Clinical exploration on: Regimen for Lower Dosing longer dosing Severe Eosinophilic Asthma Patients Benchmark S
Slide 35: 626: 2nd Generation BDCA2 mAb with BIC Potential
626: 2nd Generation BDCA2 mAb with BIC Potential SSGJ-626 Huge Marketing Potential Through inhibiting plasmacytoid dendritic cell Mechanism (pDC), the secretion of IFNα was inhibited. Thus regulating the activity of a range of immune cells Strong BDCA2 affinity (KD: 2.48E-11) Very high Degree of hum
Slide 36: 627: 1st IND approved TL1A mAb in China
627 : 1st IND approved TL1A mAb in China TL1A —A Breakthrough Target for Inflammatory Bowel Disease (IBD) Treatment: Clinical Modality Target Representative Drug Indications Characteristics MOA status Small molecule JAK1 Upadacitinib Ph3 CD Short half-life, drug resistance TNF-a Adalimumab Approved
Slide 37: 601A: Anti-VEGF mAb
601A: Anti-VEGF mAb 601A: BRVO Phase III met the primary endpoint ➢ 601 vs Ranibizumab (Control Group) for BRVO-Induced Macular Edema：At 24 weeks post-treatment, the improvement in best-corrected visual acuity (BCVA) of subjects at 24 weeks post-treatment met the primary endpoint. ✓ The dosing frequ
Slide 38: 04 Financial Review
04 Financial Review
Slide 39: Financial Analysis
Financial Analysis Net Profit Attributable to Revenue Gross Profit Net Profit Attributable to Parent Owners of the Parent Adjusted for Non-Operating Items 16.5 % YOY 17.9 % YOY 34.9% YOY 18.8 % YOY Bn RMB Bn RMB Bn RMB Bn RMB 9.1 Gross profit ratio: 86.0% 2.3 7.8 7.8 2.1 1.9 2.0 6.9 6.6 6.4 1.7 1.7
Slide 40: Increased R&D Costs, Decreased Comprehensive Finance Costs
研发费用率提升，综合财务成本进一步下降 Selling and Distribution Comprehensive Finance R&D Costs Administrative Expenses Expenses Costs Increased R&D Costs RMB Mn 3,351 • Up-front&Milestone payment 1,327 for BD deals 3,006 • Clinical research on BsAbs and other key candidates 795 59 502 43 • R&D in pre-Clinical 481 Dec
Slide 41: Obtained IFC Long-term Loan Credit
Obtained IFC Long-tern Loan Credit Obtained International Finance Corporation (IFC) granting ＄ 200 mn equivalents long-term low-interest loan credit Further optimized the company's cash Supported by IFC's The first partner of flow and financing international IFC in the structure resources to help th
Slide 42: Asset Structure Optimized
Asset Structure Optimized 2024 2023 Total Assets 24.2 Bn 23.6 Bn Net Assets Gearing Ratio Net Assets 18.0 Bn 16.5 Bn 29.4% 29.3% Gearing Ratio1 19.7% 29.3% 亿元 19.7% 12.3% 9.6% ROE 180.4 Raised to 12.3% 165.1 153.6 2023 2024 2022 2023 2024 42
Slide 43: Abundant Cash Asset Reserves
Abundant Cash Asset Reserves Operating Net Inflow Financial Resource 3.2 Bn 8.1 Bn RMB Bn RMB Bn 3.2 8.2 8.1 7.4 2.1 2.1 5.0 4.5 1.6 1.3 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 43
Slide 44: Innovative Early-Stage R&D Platform
Innovative Early-Stage R&D Platform Strategically Investing in FIC/BIC Start-ups and Empower 3S R&D from Long-term Perspective 2024 Nov 2024 Nov Lead the A+++ Participate in financing round the A+ finacing of NK CellTech round of C-RAY NK Cell Tech —— Discovery and development of innovative C-Ray Th
Slide 45: BD Strategy
BD Strategy Sufficient Financial Resource Nearly RMB 8 bn available License-Out Comprehensive Facilities 6 manufacturing plants with 100KL+ Over RMB 2 bn operating cash net cost-effective manufacturing capabilities, inflow annually covering small molecule, large • Promote the innovative products ind
Slide 46: Shareholder Return
Shareholder Return Shareholder Return • Proactive and close • Dividends and repurchase amount • Repurchased 270mn HKD in 2024, Declared Dividend for 2024： communication with investors, totaled 860mn HKD, accounting for rank ahead among healthcare conducting over 100 online over 40% of net profit of
Slide 47: Q&A
05 Q&A
Slide 48: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE